Claris Bio
Claris Biotherapeutics, Inc.
Claris Bio is dedicated to advancing transformative therapies for sight-threatening conditions where limited or no treatment options exist.
clarisbio.com · Half Moon Bay, CA
Funding event
The round itself, as filedInferred stageSeries B
Sold of offered$55.7M of $121M
Filed2026-08-07
Days since filing58
- Exemption claimed
- Rule 506(b)
- First-ever Form D
- No
- Date of first sale
- 2025-11-25
Investors
No investors named: Form D does not list them
This round was amended. Amendment filing
Officers on the filing
Names and roles as filed; addresses are never stored- Stephen BradyExecutive Officer · Director
- Reza DanaDirector
- Kenneth HarrisonDirector
- Marc de GaridelDirector
- Meredith FisherDirector
- Henry RathExecutive Officer
- Susan OrrExecutive Officer
- Michael DybbsDirector
- Matt HobsonDirector
- Maha RadhakrishnanDirector
- Clarke AtwellExecutive Officer
- Brian BaumExecutive Officer
Health flags
Three flags, each with the raw inputs behind it · as of 2026-10-03UndersubscribedFlagged45.9% sold10.3 months since first sale
Prior raiseNot flaggedPrior raise not known—
AmendedFlaggedD/A on 2026-08-12Amount offered unchanged or not stated
Open roles
On the employer's own careers page · checked 2026-09-230
Pre-posting windowNot enough dataShown once this sector and stage have 20 observed lags from filing to first posting.
No open roles foundWe read careers pages daily.
All filings
Every filing for this company, newest first, amendments includedAlso raised in Health & bio
Same sector, 28 days to 2026-10-04Altay TherapeuticsSeries A · $15.7M of $45.1M · San Carlos, CAQuietCarebilitySeries A · $8.8M of $8.8M · Richardson, TXQuiet
75 rounds in Health & bio in the 28 days to 2026-10-03, against 71 in the 28 days before.